Study S001912

Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05394519
Acronym: REDEFINE 2
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 1200
Start: 2023-02-01
Primary completion: 2025-01-28
Lead sponsor: Novo Nordisk A/S
Conditions: Overweight; Obesity; Type 2 Diabetes Mellitus
Interventions: DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo cagrilintide; DRUG:Placebo semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1267-4287; EUDRACT_NUMBER:2021-005121-24; REGISTRY:jRCT2031220671

Registered primary outcomes

Relative change in body weight [From baseline (week 0) to end of treatment (week 68)]
Achievement of greater than or equal to (≥) 5% weight reduction [From baseline (week 0) to end of treatment (week 68)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0007868	Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. Davies MJ, The New England journal of medicine	2025	Randomized trial	PMID 40544432 DOI	cites ClinicalTrials.gov:NCT05394519; registry reference DERIVED:40544432